We are studying whether olaparib can help prevent cancer recurrence in patients with p53abn endometrial cancer after they receive chemoradiation. This trial compares olaparib treatment to observation alone.
Health conditions and diseases that the clinical trial is designed to study and treat.
This condition refers to patients who have been diagnosed with p53abn HREC (a type of endometrial cancer) and have undergone surgery with the intent to cure, specifically after procedures like hysterectomy and bilateral salpingooophorectomy, without any signs of remaining disease.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.